Minimal clinically important change on the unified Parkinson's disease rating scale
Identifieur interne : 003341 ( Main/Exploration ); précédent : 003340; suivant : 003342Minimal clinically important change on the unified Parkinson's disease rating scale
Auteurs : Anette Schrag [Royaume-Uni] ; Cristina Sampaio [Portugal] ; Nicholas Counsell [Royaume-Uni] ; Werner Poewe [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-08.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Disability Evaluation, Dopamine Agents (therapeutic use), Evaluation scale, Female, Humans, Improvement, Indoles (therapeutic use), Male, Middle Aged, Nervous system diseases, Parkinson Disease (classification), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Reproducibility of Results, Treatment Outcome, UPDRS, Unified Parkinson's Disease Rating Scale, minimal clinically important change, minimal clinically meaningful improvement.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Indoles.
- classification : Parkinson Disease.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Disability Evaluation, Female, Humans, Male, Middle Aged, Reproducibility of Results, Treatment Outcome.
Abstract
The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20914
Affiliations:
- Autriche, Portugal, Royaume-Uni
- Angleterre, Grand Londres, Tyrol (Land)
- Innsbruck, Londres
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000751
- to stream Istex, to step Curation: 000751
- to stream Istex, to step Checkpoint: 001E00
- to stream PubMed, to step Corpus: 002C56
- to stream PubMed, to step Curation: 002C56
- to stream PubMed, to step Checkpoint: 002C33
- to stream Ncbi, to step Merge: 001678
- to stream Ncbi, to step Curation: 001678
- to stream Ncbi, to step Checkpoint: 001678
- to stream Main, to step Merge: 004654
- to stream PascalFrancis, to step Corpus: 001A46
- to stream PascalFrancis, to step Curation: 001275
- to stream PascalFrancis, to step Checkpoint: 001A18
- to stream Main, to step Merge: 004B13
- to stream Main, to step Curation: 003341
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
<author><name sortKey="Counsell, Nicholas" sort="Counsell, Nicholas" uniqKey="Counsell N" first="Nicholas" last="Counsell">Nicholas Counsell</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48D</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20914</idno>
<idno type="url">https://api.istex.fr/document/9A21C7C1629235028808E950CFCF237D12AFB48D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000751</idno>
<idno type="wicri:Area/Istex/Curation">000751</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E00</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Schrag A:minimal:clinically:important</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16673410</idno>
<idno type="wicri:Area/PubMed/Corpus">002C56</idno>
<idno type="wicri:Area/PubMed/Curation">002C56</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C33</idno>
<idno type="wicri:Area/Ncbi/Merge">001678</idno>
<idno type="wicri:Area/Ncbi/Curation">001678</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001678</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Schrag A:minimal:clinically:important</idno>
<idno type="wicri:Area/Main/Merge">004654</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0435092</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A46</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001275</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A18</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Schrag A:minimal:clinically:important</idno>
<idno type="wicri:Area/Main/Merge">004B13</idno>
<idno type="wicri:Area/Main/Curation">003341</idno>
<idno type="wicri:Area/Main/Exploration">003341</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Free and University College Medical School, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Counsell, Nicholas" sort="Counsell, Nicholas" uniqKey="Counsell N" first="Nicholas" last="Counsell">Nicholas Counsell</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>GlaxoSmithKline, Harlow</wicri:regionArea>
<wicri:noRegion>Harlow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Clinic, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-08">2006-08</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1200">1200</biblScope>
<biblScope unit="page" to="1207">1207</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9A21C7C1629235028808E950CFCF237D12AFB48D</idno>
<idno type="DOI">10.1002/mds.20914</idno>
<idno type="ArticleID">MDS20914</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Disability Evaluation</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Evaluation scale</term>
<term>Female</term>
<term>Humans</term>
<term>Improvement</term>
<term>Indoles (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (classification)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Reproducibility of Results</term>
<term>Treatment Outcome</term>
<term>UPDRS</term>
<term>Unified Parkinson's Disease Rating Scale</term>
<term>minimal clinically important change</term>
<term>minimal clinically meaningful improvement</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Disability Evaluation</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Reproducibility of Results</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Amélioration</term>
<term>Echelle d'évaluation</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Portugal</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
<li>Londres</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
</region>
<name sortKey="Counsell, Nicholas" sort="Counsell, Nicholas" uniqKey="Counsell N" first="Nicholas" last="Counsell">Nicholas Counsell</name>
</country>
<country name="Portugal"><noRegion><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</noRegion>
</country>
<country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003341 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003341 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48D |texte= Minimal clinically important change on the unified Parkinson's disease rating scale }}
This area was generated with Dilib version V0.6.23. |